Track topics on Twitter Track topics that are important to you
OTTAWA, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, is pleased to announce that it has entered into a two-year distribution agreement with PACC Pets. The agreement, for Avivagen’s companion animal health product VIVAMUNE HEALTH CHEWS, is for the United States only and is non-exclusive, except for the state of Florida, for which Avivagen has granted exclusive distribution rights for an initial six-month period. In addition, PACC Pets will be featuring Vivamune in the New Product Showcase at Global Pet Expo, the largest pet product industry trade show in the world, from March 21st-23rd, 2018 in Orlando, Florida.
Kym Anthony, Avivagen’s Chairman & Interim CEO stated, “We are very pleased and excited to be partnering with PACC Pets regarding our Vivamune Health Chews product and to be attending the Global Pet Expo. We view this agreement as another validation of our OxC-beta technology and we look forward to working with and expanding our relationship with this unique and innovative company and showcasing Vivamune Health Chews at Global Pet Expo.”
ABOUT PACC PETS
A growing and dynamic company, PACC Pets, LLC is dedicated to distributing innovative and unique high-quality pet products throughout the United States and Canada. Its substantial retail network includes larger retail chains, online suppliers and individual pet stores.
PACC Pets is also a global distributor with distribution connections in the following countries:
ABOUT GLOBAL PET EXPO
Vivamune will be featured at GLOBAL PET EXPO for the first time from March 21st -23rd in Orlando Florida. Presented by the American Pet Products Association (APPA) and Pet Industry Distributors Association (PIDA), Global Pet Expo is the pet industry's largest annual trade show featuring the newest, most innovative pet products on the market today.
The 2017 Showcase featured 1,130 exhibitors, 3,437 booths, 3,000 new product launches and more than 6,700 pet product buyers, including a significant number of international retailers.
2018’s Expo will include the New Products Showcase which gives exhibitors the opportunity to highlight their newest lines while getting additional exposure for their products at Global Pet Expo. It is also an opportunity for key international and domestic buyers to see what's new and exciting in the industry. The New Product Showcase receives a great deal of interest at the Show as well as coverage in numerous trade publications. With hundreds of entries, this is the largest new products showcase at any pet product industry trade show in the world.
Avivagen Inc. is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com.
About Vivamune™ Health Chews (Vivamune)
Vivamune is an all-in-one chew that can dramatically simplify a pet’s supplement routine. Featuring a newly-discovered, novel immune-supporting active ingredient: OxC-beta™ compound, Vivamune targets joints, skin and digestive health all in a single, tasty chew a pet will love. Vivamune is available for sale in the United States. For more information, visit www.vivamunehealth.com.
About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand.
Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements about the future of the distribution relationship between Avivagen Inc. and PACC Pets and about the Global Pet Expo set out in this news release are forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, the distribution relationship with PACC Pets may not have the expected outcomes, may not be successful or may not expand as anticipated. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information:
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Chairman & Interim CEO
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
Copyright © 2018 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.NEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...